[
  "human: What are the latest and highest quality treatments for diabetes? Give me 2 queries",
  "Director-Agent: What are the latest and highest quality treatments for diabetes? Give me 2 queries\n[{'index': 1, 'function': {'arguments': '{\"queries\": [\"What are the most effective and evidence-based pharmaceutical treatments for type 1 and type 2 diabetes approved in the last 5 years (2019-2024), including clinical trial results and patient outcomes?\", \"What are the latest non-pharmaceutical approaches and technologies for diabetes management, including digital health tools, artificial pancreas systems, and lifestyle interventions with strong clinical evidence?\"]}', 'name': 'execute_worker_search_agents'}, 'id': 'toolu_011FrERXsy8jjmEzZqSbRDnW', 'type': 'function'}]\nFunction 'execute_worker_search_agents' result:\nWhat are the latest non-pharmaceutical approaches and technologies for diabetes management, including digital health tools, artificial pancreas systems, and lifestyle interventions with strong clinical evidence?\n[{'function': {'arguments': '{\"query\":\"Latest non-pharmaceutical approaches for diabetes management: digital health tools, artificial pancreas systems, lifestyle interventions, and clinical evidence\"}', 'name': 'exa_search'}, 'id': 'call_99l73KQEHLnj48x8C4uLJKHM', 'type': 'function'}]\nFunction 'exa_search' result:\n{\n  \"requestId\": \"f955d9d45f757eafeccfe09529df2334\",\n  \"autopromptString\": \"Latest non-pharmaceutical approaches for diabetes management: digital health tools, artificial pancreas systems, lifestyle interventions, and clinical evidence\",\n  \"autoDate\": \"2025-07-12T00:00:00.000Z\",\n  \"resolvedSearchType\": \"neural\",\n  \"context\": \"Title: Finding the Right Automated Insulin Deliv\\n\\nTitle: Advancing Diabetes Care: Combating Burnou\\n\\n\",\n  \"results\": [\n    {\n      \"id\": \"https://www.type1strong.org/blog-post/finding-the-right-automated-insulin-delivery-system-for-you\",\n      \"title\": \"Finding the Right Automated Insulin Delivery System for You\",\n      \"url\": \"https://www.type1strong.org/blog-post/finding-the-right-automated-insulin-delivery-system-for-you\",\n      \"publishedDate\": \"2025-05-12T00:00:00.000Z\",\n      \"author\": \"Erin PocheMarch 27, 2025Erin PocheMarch 27, 2025\",\n      \"text\": \"The combination automatically adjusts insulin delivery to help control blood glucose levels and keep the ideal time in range (TIR). TIR is the happy medium those with diabetes spend with their blood sugar levels in a recommended target range. Your physician helps determine this challenging feat, and finding the right automated insulin delivery system will almost guarantee it.\\n\\nIf you’ve ever wondered what exactly an [automated insulin delivery system](https://diabetesjournals.org/care/article/45/12/3058/147674/Automated-Insulin-Delivery-Benefits-Challenges-and) (AID) is, and if it’s right for you, read on! AID or as it’s sometimes called, the artificial pancreas, is groundbreaking technology for individuals with diabetes that includes an insulin pump/pod and a continuous glucose monitoring system working in tandem.\\n\\n“Studies with various AID systems unequivocally demonstrate improvement in glycemic outcomes in people with T1D across all age groups, in all genders,” cites the Endocrine Reviews 2023.\\n\\nAs individuals with diabetes battle keeping their blood sugar in check, they also combat [hypoglycemia](https://www.cdc.gov/diabetes/basics/low-blood-sugar.html) (low blood sugar) and [hyperglycemia](https://diabetes.org/living-with-diabetes/treatment-care/hyperglycemia#:~:text=Hyperglycemia%20is%20the%20technical%20term,can't%20use%20insulin%20properly.) (high blood sugar). In addition, AID systems lessen the burden of daily diabetes management and reduce diabetes burnout while improving hemoglobin A1C (HbA1C) results.\\n\\n## What Exactly is an AID System\\n\\nAn automated insulin system combines [continuous glucose monitoring](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes/continuous-glucose-monitoring) (CGM) and an insulin pump or pod. AIDs are hybrid closed-loop systems allowing ongoing communication between the CGM and insulin pump. It’s named an artificial pancreas or bionic pump because the technology replaces the function of the pancreas.\\n\\nIn the auto-immune disorder type 1 diabetes, the immune system attacks the pancreas’ insulin-producing beta cells. Insulin assists the glucose in your bloodstream to enter the body’s cells to use for energy. Without it—the body’s cells starve, and the sugar gets trapped in the bloodstream. In severe cases, T1Ds and T2Ds may experience a life-threatening complication called [diabetic ketoacidosis](https://diabetes.org/about-diabetes/complications/ketoacidosis-dka/dka-ketoacidosis-ketones) (DKA) that may lead to diabetic coma or death if left untreated; another additional advantage of automated delivery systems! They are not only improving the quality of lives but saving them as well.\\n\\n## How the AID System Works\\n\\nThe [hybrid closed-loop technology](https://jdrf.org.uk/knowledge-support/managing-type-1-diabetes/guide-to-type-1-diabetes-technology/hybrid-closed-loop-technology-artificial-pancreas/) creates a ring of transmission between your diabetes devices, generally every five minutes. The CGM reads your blood sugar and reports the glucose level to the insulin pump or pod, recording constant fluctuations.\\n\\nThe pump/pod then adjusts the insulin delivery using algorithms to control the output. These algorithms are the brains behind the AID system. They figure out which direction your blood is headed and adjust accordingly.\\n\\n**Pro Tip**: Another benefit of AIDs is that most have unique features that protect against low blood sugar during exercise to reduce insulin delivery.\\n\\n### How Do Insulin Pumps Work\\n\\nIf you’ve wondered how insulin pumps work, these smart devices deliver insulin through a tiny catheter inserted into the skin. This site must be changed every three to four days. There is also insulin therapy now with a [surgically implanted insulin pump](https://diabetesjournals.org/care/article/15/7/877/17626/Clinical-Trial-of-Programmable-Implantable-Insulin) that lasts up to 1.7 years.\\n\\nAn insulin pump gives rapid or short-acting insulin in two ways:\\n\\n**Basal**: A small dose of insulin that continuously infuses insulin throughout the day and night.\\n\\n**Bolus**: The Insulin you take for meals or high blood sugar to correct rising blood glucose levels.\\n\\nA standard insulin pump has fixed delivery rates you determine with your doctor. Without linking to a CGM, this is a more **hands-on** approach to insulin therapy.\\n\\nWhen linked with the CGM, it’s considered a **hands-off** method for diabetes management. The continuous glucose monitor contains a tiny disposable sensor inserted under your skin. Another new type of CGM sensor may be implanted inside your body by a physician.\\n\\n**The Catch with some AID systems** is that individual users still need to bolus for food intake (carbohydrate counting) and exercise.\\n\\n## The Different Types of Automated Insulin Delivery Systems\\n\\nWith all the choices on the market, choosing the right insulin delivery system is important. Technology keeps moving forward, with new enhanced options being introduced every day. Understanding these systems and the different terminology can help you decide what is right for you.\\n\\nFirst, know that insulin pumps can be—open loop, closed loop or hybrid.\\n\\n### Open Loop System\\n\\nOpen-loop systems are when a person uses a CGM and pump, but this design needs user input. It’s not automatically entered. All manually controlled insulin delivery methods are considered open-loop—insulin pens or traditional insulin pumps/pods. All AID systems can be in open-loop mode to manually control insulin delivery.\\n\\n### Hybrid Closed Loop AID System\\n\\nHybrid closed-loop systems can be hands-off (automated). The CGM and pump/pod’s communication triggers automatic adjustments to keep glucose in the target range. With this method, the user still needs to bolus for meals and adjust for exercise, hence the hybrid system.\\n\\n**Here are a few FDA-approved hybrid closed-loop systems:**\\n\\n[Tandem t:slim x2™ insulin pump](https://www.tandemdiabetes.com/landing-pages/t-slim-x2?utm_source=google&utm_medium=cpc&utm_campaign=NPD-GGL-BR-Brand&utm_term=tandem%20tslim&gad=1&gclid=Cj0KCQjwmvSoBhDOARIsAK6aV7i7dMRJcBjOtkeMRY8yv82qZAznSUmmW9ppvX8E5aXHiIXr5Utei44aApM6EALw_wcB&gclsrc=aw.ds) with Control-IQ and Dexcom G6 or G7 CGM (age six and older)\\n\\n[Medtronic MiniMed™780G insulin pump](https://www.medtronicdiabetes.com/products/minimed-780g-insulin-pump-system?utm_source=google&utm_campaign=Pumps+-+BRAND+-+Core+-+Exact_fy24_pumps_asbly&utm_medium=cpc&gclid=Cj0KCQjwmvSoBhDOARIsAK6aV7gU_he1CBMkkyBBs7NLNrwyIwE0_YpNBlmK63fc3ILjQBq8eDr8Qo4aAmEGEALw_wcB&gclsrc=aw.ds) (age seven and older)\\n\\n[Medtronic MiniMed™770G insulin pump](https://www.medtronicdiabetes.com/products/minimed-770g-insulin-pump-system) (age two and older) and Guardian™Sensor CGM (age two and older)\\n\\n[Tandem Mobi](https://www.tandemdiabetes.com/products/tandem-mobi): Approved by the FDA in July 2023, this is the smallest AID system, fully controlled with an iPhone.\\n\\n[Omnipod®5 insulin pod](https://www.omnipod.com/simplify/omnipod-5?utm_source=google&utm_medium=paid&utm_campaign=bramo-aw&utm_content=brnd-5&ctoken=7012J000001gYaOQAU&utm_id=15993503717&ad_group_id=133362346220&gad=1) and Dexcom G6 or G7 CGM, the first tubeless AID system. (age two and up). This technology predicts trends 60 minutes out and adjusts insulin automatically designed to deliver glucose range to users.\\n\\n### Closed Loop AID Systems\\n\\nThe future lies in the [closed-looping system](https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-9-120) that does not require input for insulin dosing. The first FDA-approved closed-loop system available for ages six and up is the [iLet Bionic Pancreas](https://www.betabionics.com/ilet-bionic-pancreas/) from Beta Bionics.\\n\\nThis incredible hands-off system is virtually decision-making-free, an incredibly revolutionary management system for T1Ds. With this BIONIC system, the user only needs to enter their weight and tell the pump when they’re eating small, medium, or large meals—with no more carb counting or math for insulin dosing.\\n\\n## Changing the Future for T1Ds\\n\\nThe key takeaway is that AID systems provide overall benefits for T1Ds in achieving their target range. They also protect against low and high blood sugar levels while sleeping and reduce the burden of micromanaging glucose levels—freeing you from manually inputting and guarding your numbers around the clock.\\n\\nStay in the know and watch future trends – diabetes technology is constantly changing and transforming lives.\",\n      \"summary\": \"{\\\"answer\\\":\\\"The article discusses automated insulin delivery (AID) systems, also known as artificial pancreas systems, for managing diabetes. It explains how these systems work by combining continuous glucose monitoring (CGM) and an insulin pump or pod to automatically adjust insulin delivery. The article highlights the benefits of AID systems, including improved glycemic outcomes, reduced burden of daily diabetes management, and decreased risk of complications like hypoglycemia and diabetic ketoacidosis. It also touches upon the technology behind insulin pumps and how they deliver insulin.\\\"}\",\n      \"image\": \"https://cdn.prod.website-files.com/64eec5ed1ea74a7194cd16a3/652437666f15f501b4e8a679_1.%20%2375%20Choosing%20the%20Right%20AID%20System.jpg\"\n    },\n    {\n      \"id\": \"https://hitconsultant.net/2025/08/04/advancing-diabetes-care-combating-burnout-and-harnessing-technology/\",\n      \"title\": \"Advancing Diabetes Care: Combating Burnout and Harnessing Technology\",\n      \"url\": \"https://hitconsultant.net/2025/08/04/advancing-diabetes-care-combating-burnout-and-harnessing-technology/\",\n      \"publishedDate\": \"2025-08-04T00:00:00.000Z\",\n      \"author\": \"Our Thought Leaders\",\n      \"text\": \"- [Skip to main content](https://hitconsultant.net/hitconsultant.net#genesis-content)\\n- [Skip to secondary menu](https://hitconsultant.net/hitconsultant.net#genesis-nav-secondary)\\n- [Skip to primary sidebar](https://hitconsultant.net/hitconsultant.net#genesis-sidebar-primary)\\n- [Skip to secondary sidebar](https://hitconsultant.net/hitconsultant.net#genesis-sidebar-secondary)\\n- [Skip to footer](https://hitconsultant.net/hitconsultant.net#genesis-footer-widgets)\\n\\n- [LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F&title=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology&summary=As%20healthcare%20providers%2C%20we%20find%20ourselves%20at%20an%20exciting%20crossroads%20in%20diabetes%20management.%20Rapid%20advancements%20in%20technology%E2%80%94from%20RPM...&mini=true)\\n- [Twitter](https://x.com/intent/tweet?text=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology&url=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F)\\n- [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F&t=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology)\\n- [Email](mailto://hitconsultant.net?subject=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology&body=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F)\\n- [Print](https://hitconsultant.net/hitconsultant.net)\\n\\n**Mark Clements, M.D., Ph.D. Chief Medical and Strategy Officer, Glooko**\\n\\nAs healthcare providers, we find ourselves at an exciting crossroads in diabetes management. Rapid advancements in technology—from remote patient monitoring to artificial intelligence—have fundamentally altered how we approach patient care. Yet, despite these technological leaps, a critical ingredient remains consistently underrepresented: the clinician’s voice, and the voices of people with diabetes.For nearly two decades as a pediatric endocrinologist, I’ve witnessed firsthand the immense potential and significant challenges of integrating digital solutions into everyday diabetes care for both people with diabetes and their care providers. On any given day, a clinician managing diabetes navigates multiple complex responsibilities: reviewing continuous glucose monitoring (CGM) and/or meter data, keeping up with rapidly emerging devices and technologies, adjusting insulin regimens, coaching individuals with diabetes on lifestyle management, documenting clinical decisions, and coordinating care teams. For example, a single patient using a CGM device can generate up to 288 glucose data points daily, creating a complex datastream that requires detailed analysis and review. 1 Insulin pumps generate even more complicated data for review. Multiply this by dozens of people with diabetes seen by a clinician each day, and the clinician workload becomes enormous.\\n\\nPeople with diabetes echo similar concerns. Many describe data fatigue from constant management and analysis of their glucose levels. As one person stated, “The data is overwhelming; without clear insights and simpler ways to interpret it, it’s just noise.”While these data are incredibly helpful to inform clinical decision making, they can come with unintended consequences. For clinicians and people with diabetes alike, burnout is alarmingly high. Among endocrinologists in particular, approximately half to two-thirds of clinicians report burnout symptoms. 2,3 Bureaucratic tasks, prolonged work hours, and the burden of data review contribute significantly to this stress, making effective integration of data and devices into their daily workflows critical.\\n\\nSimilarly, people with diabetes report significant stress from managing their condition daily. “Every glucose reading feels like a test I can fail,” is something I have heard before in the clinic. Effective  integration of data into one’s daily experience of living with diabetes could alleviate such emotional burdens by making data actionable, intuitive, and less intrusive.Individuals with diabetes  and the clinicians who care for them hold critical insights into behaviors, challenges with engagement in self-management, and care preferences. Yet, digital solutions are frequently developed without adequate input from clinicians and people with diabetes, leading to sophisticated but impractical tools. Only about 40% of digital diabetes solutions see active clinical use, largely due to poor workflow integration.4 True interoperability through electronic health record (EHR integration) and streamlined integration into clinicians’ flow of work are essential to increasing adoption and effectiveness. People with diabetes also stress the importance of simplicity and intuitive user experiences: If the technology is complicated, it just becomes another barrier.\\n\\nConnected care, where user-generated data integrate seamlessly with clinical decision-making, represents the clear future of diabetes management. Evidence shows connected care platforms can support remote healthcare delivery in a way that significantly improves diabetes outcomes, including reductions of HbA1c levels up to 1.5% and decreased hypoglycemic episodes.5 Such platforms enable clinicians to rapidly identify high-risk patterns and deliver proactive rather than reactive interventions. For people with diabetes, this can lead to significant improvements in their diabetes self-management.AI-driven predictive analytics are also emerging as powerful tools. These can forecast impending hypoglycemic or hyperglycemic events, allowing for timely preventive interventions. Automating routine data analysis tasks can reduce clinician documentation time by approximately 30%, significantly alleviating administrative burdens. 6,7Looking forward, diabetes technology should aim for direct user engagement in design efforts,  and in achieving personalized approaches via robust connected care ecosystems. Advanced analytics and AI-driven decision support informed by near-real-time clinical data can transform care from generalized treatment protocols to highly personalized management strategies.Innovation guided directly by clinicians and people with diabetes is essential for meaningful progress in diabetes care. By integrating the expertise of clinicians and persons with diabetes into the earliest stages of technology development, we ensure tools genuinely enhance clinical workflows, support self-care, and ultimately personalize diabetes management, by leaning on both the science and art of human-centered design.\\n\\n## **References**\\n\\n1. Speakman, ASHP.\\n2. Hammes et al., Endocrine News; Medscape Endocrinologist Lifestyle Report, 2022.\\n3. Batta et al., BMJ Open Diabetes Res Care.\\n4. Shah et al., J. Diabetes Sci Technol., 2023.\\n5. Su et al., J. Med Internet Res., 2023.\\n6. AMA Digital Health Report.\\n7. Sidharthan et al., Scientific Reports, 2025.\\n\\n**About Mark Clements, M.D., Ph.D.**\\n\\nDr. Mark Clements currently serves as Chief Medical and Strategy Officer of Glooko, a leading global diabetes data management company. Prior to his latest role, he served as fractional Chief Medical Officer of Glooko, as well as Professor of Pediatrics at the University of Missouri-Kansas City (UMKC) School of Medicine, where he held the Endowed Chair in Endocrinology and Diabetes. At UMKC, Dr. Clements also held the role of Medical Director of the Pediatric Clinical Research Unit and the Diabetes Research Program and was Co-Principal Investigator of the TrialNet Clinical Center and Data Science Lead for the Type 1 Diabetes Exchange-Quality Improvement (T1DX-QI) initiative.\\n\\n- [LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F&title=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology&summary=As%20healthcare%20providers%2C%20we%20find%20ourselves%20at%20an%20exciting%20crossroads%20in%20diabetes%20management.%20Rapid%20advancements%20in%20technology%E2%80%94from%20RPM...&mini=true)\\n- [Twitter](https://x.com/intent/tweet?text=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology&url=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F)\\n- [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F&t=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology)\\n- [Email](mailto://hitconsultant.net?subject=Advancing%20Diabetes%20Care%3A%20Combating%20Burnout%20and%20Harnessing%20Technology&body=https%3A%2F%2Fhitconsultant.net%2F2025%2F08%2F04%2Fadvancing-diabetes-care-combating-burnout-and-harnessing-technology%2F)\\n- [Print](https://hitconsultant.net/hitconsultant.net)\\n\\n## Reader Interactions\\n\\n## Footer\\n\\n### Company\\n\\n- [About Us](https://hitconsultant.net/about-us/)\\n- [Advertise with Us](https://hitconsultant.net/advertise/)\\n- [Reprints and Permissions](https://hitconsultant.net/reprints-permissions/)\\n- [Submit An Op-Ed](https://hitconsultant.net/contributors/)\\n- [Contact](https://hitconsultant.net/contact/)\\n- [Subscribe](https://hitconsultant.net/subscribe/)\\n\\n### Editorial Coverage\\n\\n- [Opinion](https://hitconsultant.net/category/opinion/)\\n- [Health IT](https://hitconsultant.net/category/health-it/)\\n - [Care Coordination](https://hitconsultant.net/tag/care-coordination/)\\n - [EMR/EHR](https://hitconsultant.net/category/emr-ehr/)\\n - [Interoperability](https://hitconsultant.net/tag/health-it-interoperability/)\\n - [Population Health Management](https://hitconsultant.net/category/technology/population-health-management-technology/)\\n - [Revenue Cycle Management](https://hitconsultant.net/tag/revenue-cycle-management/)\\n- [Digital Health](https://hitconsultant.net/category/digital-health-2/)\\n - [Artificial Intelligence](https://hitconsultant.net/tag/artificial-intelligence/)\\n - [Blockchain Tech](https://hitconsultant.net/tag/healthcare-blockchain/)\\n - [Precision Medicine](https://hitconsultant.net/tag/precision-medicine/)\\n - [Telehealth](https://hitconsultant.net/category/technology/telehealth-2/)\\n - [Wearables](https://hitconsultant.net/category/digital-health-2/wearables/)\\n- [Startups](https://hitconsultant.net/category/startups/)\\n- [Value-Based Care](https://hitconsultant.net/tag/value-based-care/)\\n - [Accountable Care](https://hitconsultant.net/category/policy/aco/)\\n - [Medicare Advantage](https://hitconsultant.net/tag/medicare-advantage/)\\n\\n### Connect\\n\\n### Subscribe to HIT Consultant Media\\n\\nLatest insightful articles delivered straight to your inbox weekly\",\n      \"summary\": \"{\\\"answer\\\":\\\"The article discusses the use of technology in diabetes management, including remote patient monitoring and artificial intelligence. It highlights the challenges of integrating digital solutions, such as data fatigue and clinician burnout. The article mentions the need for clear insights and simpler ways to interpret data. It also mentions the use of continuous glucose monitoring (CGM) and insulin pumps, and the large amount of data they generate. The article does not specifically mention non-pharmaceutical approaches like digital health tools, artificial pancreas systems, lifestyle interventions, and clinical evidence, but it does touch on the use of technology and the need for simpler data interpretation.\\\"}\",\n      \"image\": \"https://hitconsultant.net/wp-content/uploads/2025/08/Mark-Clements-1-scaled.jpg\",\n      \"favicon\": \"https://hitconsultant.net/wp-content/themes/magazine-pro/images/favicon.ico\"\n    }\n  ],\n  \"searchTime\": 3248.9,\n  \"costDollars\": {\n    \"total\": 0.009,\n    \"search\": {\n      \"neural\": 0.005\n    },\n    \"contents\": {\n      \"text\": 0.002,\n      \"summary\": 0.002\n    }\n  }\n}\n**Executive Summary**  \nRecent literature highlights substantial advancements in non-pharmaceutical diabetes management, particularly through automated insulin delivery (AID) systems (artificial pancreas), digital health tools, and connected care platforms. These technologies improve glycemic outcomes, reduce management burden, and show promise in addressing both clinical and psychosocial challenges, though integration into daily life and clinical practice remains a key hurdle.\n\n---\n\n**Introduction: Context and Scope**  \nDiabetes management is evolving rapidly with the advent of non-pharmaceutical interventions, including digital health tools, artificial pancreas systems, and lifestyle-focused technologies. This synthesis reviews the latest evidence and expert commentary on these approaches, focusing on their clinical efficacy, user experience, integration challenges, and future directions.\n\n---\n\n**Main Findings by Theme**\n\n**1. Automated Insulin Delivery (AID) and Artificial Pancreas Systems**  \n- AID systems combine continuous glucose monitoring (CGM) and insulin pumps to automatically adjust insulin delivery, aiming to maintain blood glucose within the target range (Type1Strong, 2025).\n- Clinical evidence, including Endocrine Reviews 2023, demonstrates unequivocal improvement in glycemic outcomes (e.g., HbA1c reduction, increased time-in-range) across all age groups and genders.\n- AID systems reduce risks of hypoglycemia, hyperglycemia, and diabetic ketoacidosis, and lessen daily management burden and diabetes burnout.\n- Types of AID:\n  - **Open-loop**: Requires manual input for insulin dosing.\n  - **Hybrid closed-loop**: Automates basal insulin adjustments but still requires user input for meals and exercise.\n  - **Closed-loop**: Fully automated (e.g., iLet Bionic Pancreas), requiring minimal user input.\n- FDA-approved systems include Tandem t:slim x2, Medtronic MiniMed 780G/770G, Tandem Mobi, Omnipod 5, and the iLet Bionic Pancreas.\n\n**2. Digital Health Tools and Connected Care**  \n- Technologies such as remote patient monitoring, CGMs, and AI-driven platforms are increasingly central to diabetes care (HIT Consultant, 2025).\n- Connected care platforms integrating user-generated data with clinical workflows can significantly improve outcomes (e.g., HbA1c reduction up to 1.5%, fewer hypoglycemic episodes).\n- AI analytics can predict adverse glycemic events and streamline clinician documentation, reducing administrative burden by up to 30%.\n\n**3. User Experience and Burnout**  \n- Both clinicians and patients experience data fatigue and burnout due to the complexity and volume of data generated by modern devices.\n- Only about 40% of digital diabetes solutions see active clinical use, often due to poor workflow integration and lack of user-centered design.\n- Simplicity, intuitive interfaces, and direct user involvement in technology development are critical for adoption and effectiveness.\n\n---\n\n**Critical Analysis of Evidence Quality**  \n- The Type1Strong article synthesizes clinical trial data and FDA regulatory information, referencing authoritative sources such as Endocrine Reviews and the CDC.\n- The HIT Consultant piece, authored by a leading clinician and referencing peer-reviewed studies (BMJ Open Diabetes Res Care, J. Med Internet Res., Scientific Reports), provides expert insight into real-world implementation and challenges.\n- Both sources are recent (2025) and reflect current clinical and technological landscapes, though the HIT Consultant article is more opinion-focused and less specific about individual interventions.\n\n**Synthesis of Key Insights and Patterns**  \n- There is convergent evidence that AID systems and digital health platforms improve glycemic control and reduce complications.\n- The greatest barriers are not technological efficacy but workflow integration, user fatigue, and the need for human-centered design.\n- The movement toward fully closed-loop systems and AI-powered analytics represents a paradigm shift toward less burdensome, more personalized diabetes care.\n\n---\n\n**Limitations and Gaps Identified**  \n- Neither source provides robust long-term data on lifestyle interventions or comparative effectiveness between different non-pharmaceutical tools.\n- There is limited discussion of cost, access, and disparities in adoption.\n- The psychosocial impact of these technologies, while acknowledged, warrants further quantitative study.\n\n---\n\n**Evidence-Based Conclusions**  \n- Non-pharmaceutical approaches, especially AID systems and connected digital health platforms, are transforming diabetes management, with strong evidence for improved clinical outcomes and reduced management burden.\n- Successful implementation depends on seamless integration into daily life and clinical workflows, prioritizing user experience and clinician input.\n- Ongoing challenges include addressing data overload, ensuring equitable access, and validating long-term benefits across diverse populations.\n\n---\n\n**Future Research Directions**  \n- Comparative studies on the effectiveness of various AID systems and digital platforms.\n- Longitudinal research on psychosocial outcomes and quality of life.\n- Evaluation of cost-effectiveness and strategies to reduce disparities in access.\n- Development and testing of user-centered design frameworks for diabetes technology.\n\n---\n\n**Errors or Issues in Tool Output**  \n- No major errors were detected; however, the summary for the HIT Consultant article underrepresents its discussion of connected care and clinical evidence.\n- The tool output did not capture lifestyle interventions in depth, reflecting a gap in the source material rather than a technical error.\n\n---\n\n**References**  \n- Type1Strong. (2025). Finding the Right Automated Insulin Delivery System for You. https://www.type1strong.org/blog-post/finding-the-right-automated-insulin-delivery-system-for-you  \n- HIT Consultant. (2025). Advancing Diabetes Care: Combating Burnout and Harnessing Technology. https://hitconsultant.net/2025/08/04/advancing-diabetes-care-combating-burnout-and-harnessing-technology/  \n- Endocrine Reviews (2023); CDC; BMJ Open Diabetes Res Care; J. Med Internet Res.; Scientific Reports (2025). [Cited within source texts] What are the most effective and evidence-based pharmaceutical treatments for type 1 and type 2 diabetes approved in the last 5 years (2019-2024), including clinical trial results and patient outcomes?\n[{'function': {'arguments': '{\"query\":\"Most effective and evidence-based pharmaceutical treatments for type 1 and type 2 diabetes approved 2019-2024, including clinical trial results and patient outcomes\"}', 'name': 'exa_search'}, 'id': 'call_19EKekOHno7BdWHVXiBfJ6sN', 'type': 'function'}]\nFunction 'exa_search' result:\n{\n  \"requestId\": \"485c11de5715c98bcdf1a7a5dc7baa8d\",\n  \"autopromptString\": \"Most effective and evidence-based pharmaceutical treatments for type 1 and type 2 diabetes approved 2019-2024, including clinical trial results and patient outcomes\",\n  \"autoDate\": \"2019-01-01T00:00:00.000Z\",\n  \"resolvedSearchType\": \"neural\",\n  \"context\": \"Title: Evaluation and comparison of efficacy and\\n\\nTitle: Tirzepatide: A Review in Type 2 Diabetes \\n\\n\",\n  \"results\": [\n    {\n      \"id\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11668020/\",\n      \"title\": \"Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis\",\n      \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11668020/\",\n      \"publishedDate\": \"2024-12-24T00:00:00.000Z\",\n      \"author\": \"\",\n      \"text\": \"\\n \\n \\n \\n Abstract \\n Objective \\n The objective is to assess the effectiveness and safety of tirzepatide, liraglutide, and SGLT2i in individuals diagnosed with type 2 diabetes. Methods \\n An inquiry was undertaken within the electronic database spanning from its inception to February 11th, 2024, aimed at identifying randomized controlled trials that assess the efficacy and safety of tirzepatide, liraglutide, canagliflozin, ertugliflozin, empagliflozin, dapagliflozin, and henagliflozin. Perform a network meta-analysis to examine the distinctions among them (PROSPERO registration number: CRD42024537006). Results \\n Twenty-eight RCTs were included, involving 8499 participants. Compared with placebo, all treatments improved HbA1c levels: tirzepatide 15 mg reduced HbA1c the most (MD [95% CI], -2.24% [-2.52, -1.96]%), followed by tirzepatide 10 mg (MD [95% CI], -1.99% [-2.29, -1.69]%), tirzepatide 5 mg (MD [95% CI], -1.82% [-2.11, -1.53]%), and liraglutide 1.2 mg (MD [95% CI], -1.23% [-1.41, -1.05]%). Canagliflozin 300 mg also showed a significant reduction in HbA1c (MD [95% CI], -1.00% [-1.18, -0.82]). Tirzepatide was also the most effective in promoting weight loss, with the following results compared with placebo: tirzepatide 15 mg (MD [95% CI], -8.74 kg [-9.83, -7.66] kg), tirzepatide 10 mg (MD [95% CI], -7.13 kg [-8.40, -5.88] kg), tirzepatide 5 mg (MD [95% CI], -5.38 kg [-6.65, -4.11] kg), canagliflozin 300 mg (MD [95% CI], -2.31 kg [-2.79, -1.83] kg), and empagliflozin 10 mg (MD [95% CI], -2.00 kg [-2.44, -1.55] kg). In reducing systolic blood pressure (SBP), canagliflozin 300 mg showed the greatest effect (MD [95% CI], -5.96% [-7.96, -3.96] %). For diastolic blood pressure (DBP), henagliflozin 5 mg demonstrated the most significant reduction compared to placebo (MD [95% CI], -2.46% [-3.82, -1.10] %). Liraglutide 1.8 mg was most likely to cause adverse events (AE) (OR [95% CI], 2.57 [1.78, 3.70]), but there was no significant difference in serious adverse events (SAEs) between the interventions (including placebo). Conclusion \\n Out of the seven medications examined in this study, tirzepatide demonstrates the most effective antidiabetic and weight-reducing effects. Furthermore, the dosage of Liraglutide at 1.2 mg and above demonstrates a more pronounced hypoglycemic effect in comparison to SGLT2 inhibitors. SGLT2 inhibitors exhibit a distinct hypotensive effect and are suitable for diabetic individuals experiencing hypertension. Supplementary Information \\n The online version contains supplementary material available at 10.1186/s12902-024-01805-z. Keywords: Tirzepatide, Liraglutide, SGLT2i, Type 2 diabetes mellitus, Meta-analysis Introduction \\n Diabetes affects approximately 537 million individuals worldwide, leading to chronic hyperglycemia that progressively damages multiple organs, including the retina, kidneys, nerves, blood vessels, and heart, with the potential to result in organ failure [ 1]. Moreover, a growing body of evidence indicates a close association between diabetes and an increased risk of various cancers [ 2]. The 10th IDF Diabetes Map illustrates that diabetes represents one of the most rapidly escalating global health crises of the twenty-first century. Projections indicate that the population of individuals with diabetes is expected to rise to 643 million by the year 2030 and further escalate to 783 million by 2045 [ 3]. Due to the high prevalence of diabetes and its detrimental effects on several bodily systems, treating diabetic patients has consistently posed a challenging issue for physicians across various fields. In recent 30 years, a series of new hypoglycemic drugs have emerged, such as GIP/GLP-1 double receptor agonists [ 4, 5], SGLT-2 inhibitors [ 6, 7] and GLP1 receptor agonists [ 8]. In contrast to certain conventional hypoglycemic medications, these alternatives show enhanced safety, greater efficacy, and increased simplicity, while also considering the protective benefits for cardiac and renal health. SGLT-2 inhibitors [ 6, 7] and GLP1 receptor agonists have been widely used in clinics. In May 2022, the first dual agonist of glucose-dependent insulinotropic peptide (GIP) and GLP-1 receptor, tizepatide, was approved for marketing by FDA. The half-life is about 5 days, allowing for administration weekly, which enhances its practicality of use. Current research indicates that teixeptide has the potential to significantly enhance blood sugar regulation and facilitate weight loss in individuals diagnosed with type 2 diabetes [ 4, 5].\\n \\n The SGLT-2 inhibitor is a novel oral hypoglycemic medication that has garnered significant interest in recent times. It can inhibit the reabsorption of glucose by the kidney, lower the renal glucose threshold, thus promoting the excretion of urine glucose, and can significantly reduce the occurrence of cardiovascular adverse events and end-stage renal diseases [ 9, 10]. Liraglutide is a prominent medication belonging to the class of GLP1 receptor agonists. The mechanism operates by enhancing insulin secretion to reduce blood glucose levels while concurrently inhibiting glucagon secretion to increase blood sugar levels, all of which is contingent upon insulin's role. This medication proficiently lowers blood sugar levels by suppressing the appetite center, prolonging gastric emptying, and diminishing food consumption. Additionally, it has a minimal risk of causing hypoglycemia. At the same time, it also has a protective effect on the heart and kidney [ 8, 11]. \\n While prior studies, including those by Ding et al. [ 5], Guan et al. [ 12], and Thomas et al. [ 13], have analyzed specific hypoglycemic agents or focused on single drug classes, our study offers a comprehensive network meta-analysis that compares three major classes of antidiabetic medications—GLP-1 receptor agonists, GIP/GLP-1 dual receptor agonists, and SGLT-2 inhibitors—within a unified analytical framework. This approach enables both direct and indirect comparisons of efficacy and safety outcomes, including HbA1c reduction, weight loss, blood pressure control, and adverse events, across a broad spectrum of drug dosages. Unlike previous studies, which often emphasize pharmacokinetic or mechanistic insights, our analysis is guided by clinical relevance, addressing the practical application of these therapies in managing Type 2 diabetes, particularly in patients with comorbid conditions such as obesity and hypertension. Through the evaluation of these therapies according to their efficacy and safety profiles, our findings offer critical insights to evidence-based guidelines, equipping clinicians with a more nuanced understanding of optimal therapy selections and potential combinations for tailored patient management. \\n The comparative effectiveness and safety of these three drug classes have not been thoroughly assessed in relation to each other, given their distinct mechanisms of action. Network meta-analysis (NMA) serves as an ideal statistical approach to address this gap. As a method that allows for the simultaneous comparison and ranking of multiple interventions through both direct and indirect evidence, NMAs consolidate findings from multiple comparators into a single pooled analysis [ 14]. Consequently, our study employs NMA to evaluate and compare the efficacy and safety of the GIP/GLP-1 dual receptor agonist tirzepatide (TIR), the GLP-1 receptor agonist liraglutide (LIR), and various SGLT-2 inhibitors, including canagliflozin (Can), ertugliflozin (Ert), empagliflozin (Emp), dapagliflozin (Dap), and henagliflozin (Hen), in the treatment of Type 2 diabetes mellitus. Our goal is to provide evidence-based insights that can assist clinicians in formulating optimal hypoglycemic regimens. Methods \\n This systematic review and network meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines to ensure rigorous and transparent reporting of findings. The study protocol was registered on PROSPERO (ID: CRD42024537006), and we adhered to the PRISMA checklist throughout all phases of study selection, data extraction, and analysis to meet the highest reporting standards in systematic reviews and meta-analyses [ 15]. \\n Search strategy \\n Systematic searches were conducted across PubMed, EMBASE, and the Cochrane Library from database inception to February 11, 2024, using a defined set of keywords and Boolean operators to identify randomized clinical trials (RCTs) evaluating the efficacy and safety of tirzepatide, liraglutide, canagliflozin, ertugliflozin, empagliflozin, dapagliflozin, and henagliflozin, detailed search strategies tailored to each database are provided in Supplementary File 1. Duplicate records were removed through Endnote 20. Study selection criteria \\n Studies were included in this meta-analysis based on the following PICO (Population, Intervention, Comparator, Outcomes) criteria: Population – individuals diagnosed with type 2 diabetes, aged 18 years or older; Intervention – treatment with different doses of tirzepatide (Tir), liraglutide (Lir), canagliflozin (Can), ertugliflozin (Ert), empagliflozin (Emp), dapagliflozin (Dap), or henagliflozin (Hen); Comparator – placebo or any one or more of the included intervention drugs; Outcomes – efficacy outcomes, such as reductions in HbA1c, changes in body weight, and blood pressure, as well as safety outcomes, including adverse events (AEs) and serious adverse events (SAEs). \\n Studies were excluded if they met any of the following criteria: secondary analysis of published RCTs, ongoing or completed experiments with unpublished results, conference papers, review articles, animal or in vitro studies, editorials, letters, statements, or if the data were incomplete or could not be extracted. Data collection and quality assessment \\n Two researchers (X.P.Y and X.F.) independently conducted literature screening, data extraction, and quality assessment. Extracted data included the first author, publication year, intervention measures, sample size, baseline characteristics, changes in monitored indicators, intervention duration, and adverse events. For quality assessment, the RevMan5.4 program and the Cochrane risk of bias tool were used to evaluate each study across seven domains, categorizing each domain as low risk, high risk, or unclear risk [ 16]. Discrepancies were resolved through discussion between the two researchers (X.P.Y and X.F.), with a third author (Y.J.T), consulted when necessary to reach a consensus. Data analysis \\n The statistical analysis was performed utilizing Stata 17.0. Continuous variables employ the mean difference (MD) to gauge the extent of the effect, whereas binary variables utilize the odds ratio (OR) to assess the size of the effect. The confidence interval (CI) is set to 95% CI. Chi-square (χ 2) was used to test the statistical heterogeneity between the evaluation results, and I 2 was used to quantitatively judge the heterogeneity. P  &gt; 0.05, or I 2  &lt; 50% means that there is no heterogeneity, and the fixed effect model is used. P  ≤ 0.05, or I 2  ≥ 50% is heterogeneity. The random effect model and sensitivity analysis are employed to establish the origin of heterogeneity. Determine the cumulative ranking curve (SUCRA) to evaluate the therapeutic effects of different therapies and arrange them in order of effectiveness (Table 2). \\n Table 2. \\n SUCRA sorting summary \\n \\n \\n \\n Treatment \\n Outcomes \\n \\n \\n \\n HbA1c \\n Weight \\n SBP \\n DBP \\n AE \\n SAE \\n \\n \\n \\n \\n Placebo \\n 0 \\n 9.5 \\n 2.5 \\n 8.3 \\n 31.1 \\n 60.8 \\n \\n \\n Tir5mg \\n 89.6 \\n 88.9 \\n NA \\n NA \\n 74.4 \\n 68.6 \\n \\n \\n Tir10mg \\n 94 \\n 94.4 \\n NA \\n NA \\n 76.6 \\n 58.3 \\n \\n \\n Tir15mg \\n 99.7 \\n 100 \\n NA \\n NA \\n 79.3 \\n 31.4 \\n \\n \\n Lir0.6mg \\n 43.8 \\n 0.9 \\n NA \\n NA \\n NA \\n 41.2 \\n \\n \\n Lir1.2mg \\n 80.6 \\n 6.5 \\n NA \\n NA \\n NA \\n 48.5 \\n \\n \\n Lir1.8mg \\n 79.7 \\n 16.9 \\n NA \\n NA \\n 98.6 \\n 60.9 \\n \\n \\n Can100mg \\n 54 \\n 48.8 \\n 55.1 \\n 69.7 \\n 56.1 \\n 49.1 \\n \\n \\n Can200mg \\n 59.4 \\n 52.5 \\n 66.1 \\n 65.3 \\n 66.7 \\n 44.3 \\n \\n \\n Can300mg \\n 67.5 \\n 78.4 \\n 82.1 \\n 72.6 \\n 56.7 \\n 34.2 \\n \\n \\n Ert5mg \\n 24.9 \\n 60.2 \\n 68.1 \\n 46.8 \\n 19.9 \\n 82.9 \\n \\n \\n Ert15mg \\n 42 \\n 60.8 \\n 46.3 \\n 46.1 \\n 32.7 \\n 65.6 \\n \\n \\n Emp5mg \\n 20.6 \\n 41.3 \\n 12.3 \\n 15.3 \\n 10.7 \\n 25.5 \\n \\n \\n Emp10mg \\n 30.2 \\n 65.6 \\n 28.1 \\n 28.4 \\n 6.8 \\n 66.2 \\n \\n \\n Emp25mg \\n 44.2 \\n 61.8 \\n 33 \\n 46.6 \\n 11.4 \\n 47.5 \\n \\n \\n Dap5mg \\n 9.4 \\n 39.6 \\n 76.1 \\n NA \\n 43.4 \\n 36.3 \\n \\n \\n Dap10mg \\n 14 \\n 60.7 \\n 50.3 \\n NA \\n 58.3 \\n 28.8 \\n \\n \\n Hen5mg \\n 45.9 \\n 30.8 \\n 59.8 \\n 78.5 \\n 56.8 \\n 65.2 \\n \\n \\n Hen10mg \\n 50.5 \\n 32.3 \\n 70 \\n 72.5 \\n 70.4 \\n 34.7 \\n \\n \\n \\n Results \\n Study selection and characteristics \\n Some doses of drugs in the RCTs were seldom used in clinical settings, or the number of subjects was too small. Two researchers (X.P.Y and X.F.) decided to exclude the following intervention measures: tirzepatide 1 mg, tirzepatide 12 mg, liraglutide 0.1 mg, liraglutide 0.3 mg, liraglutide 0.9 mg, canagliflozin 50 mg, empagliflozin 50 mg, and dapagliflozin 2.5 mg. According to the retrieval strategy, a total of 8673 articles were retrieved, and 28 articles [ 17 – 44] remained after de-duplication, primary screening, and re-screening, involving 8499 patients. See Fig. 1 for the process and results of literature screening, Fig. 2 for literature quality evaluation, and Table 1 for baseline characteristics. The intervention duration ranged from 4 to 52 weeks, including 4-week RCT1, 8-week RCT1, 5-week RCT1, 14-week RCT1, 24-week RCT8, 26-week RCT8, 28-week RCT1, 40-week RCT1, and 52-week RCT2. The network diagram presented below illustrates all outcome indicators. Each node (blue dot) represents an intervention; the size of each node reflects the number of participants in the intervention, with larger nodes indicating more participants. The connecting line between two points signifies a direct comparison between the two interventions; the thicker the line, the more studies available to compare the two interventions. Out of the 28 documents analyzed, one presented a significant risk in terms of potential blindness and the reliability of the data obtained [ 31]. Another document [ 32] included a single-blind component in the experimental process, allowing researchers to adjust medications. See Fig. 3 for the specific evaluation structure. \\n Fig. 1. \\n \\n The process and results of literature screening Fig. 2. \\n \\n Literature quality evaluation Table 1. \\n Baseline data \\n \\n \\n Study \\n Gender(M/F) \\n Age \\n N \\n Treatment \\n Duration (weeks) \\n Outcomes \\n \\n \\n \\n Rosenstock, et al. (2021) [ 17] \\n 56/59 \\n 53.6 ± 12.8 \\n 115 \\n Placebo \\n 40 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 56/65 \\n 54.1 ± 11.9 \\n 121 \\n Tir 5mg \\n \\n \\n \\n \\n 72/49 \\n 55.8 ± 10.4 \\n 121 \\n Tir 10mg \\n \\n \\n \\n \\n 63/58 \\n 52.9 ± 12.3 \\n 121 \\n Tir 15mg \\n \\n \\n \\n \\n Frias, et al. (2020) [ 18] \\n 12/14 \\n 56.0 ± 10.13 \\n 26 \\n Placebo \\n 12 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 16/13 \\n 55.5 ± 8.54 \\n 29 \\n Tir 15mg \\n \\n \\n \\n \\n Frias, et al. (2018) [ 19] \\n 29/22 \\n 56.6 ± 8.9 \\n 51 \\n Placebo \\n 26 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 34/21 \\n 57.9 ± 8.2 \\n 55 \\n Tir 5mg \\n \\n \\n \\n \\n 30/21 \\n 56.5 ± 9.9 \\n 51 \\n Tir 10mg \\n \\n \\n \\n \\n 22/31 \\n 56.0 ± 7.6 \\n 53 \\n Tir 15mg \\n \\n \\n \\n \\n Heise, et al. (2022) [ 20] \\n 21/7 \\n 60.4 ± 7.6 \\n 28 \\n Placebo \\n 28 \\n Weight,AE, SAE \\n \\n \\n 31/14 \\n 61.1 ± 7.1 \\n 45 \\n Tir 15mg \\n \\n \\n \\n \\n Blonde, et al. (2020) [ 21] \\n 58/42 \\n 56.0 ± 9.9 \\n 100 \\n Placebo \\n 26 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 125/78 \\n 54.7 ± 10.1 \\n 203 \\n Lir 1.8mg \\n \\n \\n \\n \\n Harder, et al. (2004) [ 22] \\n 1/11 \\n 60.1 ± 6.7 \\n 12 \\n Placebo \\n 8 \\n HbA1c,Weight \\n \\n \\n 11/10 \\n 59.9 ± 11.0 \\n 21 \\n Lir 0.6mg \\n \\n \\n \\n \\n Seino, et al. (2008) [ 23] \\n 29/17 \\n 57.5 ± 8.7 \\n 46 \\n Placebo \\n 14 \\n HbA1c,Weight \\n \\n \\n 28/17 \\n 60 ± 7.0 \\n 45 \\n Lir 0.6mg \\n \\n \\n \\n \\n Marre, et al. (2009) [ 24] \\n 54/60 \\n 54.7 ± 10.0 \\n 114 \\n Placebo \\n 26 \\n HbA1c,Weight, SAE \\n \\n \\n 126/107 \\n 55.7 ± 9.9 \\n 233 \\n Lir 0.6mg \\n \\n \\n \\n \\n 102/126 \\n 57.7 ± 9.0 \\n 228 \\n Lir 1.2mg \\n \\n \\n \\n \\n 124/110 \\n 55.6 ± 10.0 \\n 234 \\n Lir 1.8mg \\n \\n \\n \\n \\n Russell-Jones, et al. (2009) [ 25] \\n 56/59 \\n 57.5 ± 9.6 \\n 115 \\n Placebo \\n 26 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 132/100 \\n 57.6 ± 9.5 \\n 232 \\n Lir 1.8mg \\n \\n \\n \\n \\n Yale, et al. (2017) [ 26] \\n 41/28 \\n 64.3 ± 7.76 \\n 69 \\n Placebo \\n 52 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 37/37 \\n 64.3 ± 8.49 \\n 74 \\n Can 100mg \\n \\n \\n \\n \\n 42/30 \\n 65.8 ± 7.88 \\n 72 \\n Can 300mg \\n \\n \\n \\n \\n Kadowaki, et al. (2017) [ 27] \\n 53/15 \\n 56.0 ± 9.5 \\n 68 \\n Placebo \\n 24 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 54/16 \\n 58.4 ± 8.9 \\n 70 \\n Can 100mg \\n \\n \\n \\n \\n Inagaki, et al. (2013) [ 28] \\n 54/21 \\n 57.7 ± 11.0 \\n 75 \\n Placebo \\n 12 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 52/22 \\n 57.7 ± 10.5 \\n 74 \\n Can 100mg \\n \\n \\n \\n \\n 49/27 \\n 57.0 ± 10.7 \\n 76 \\n Can 200mg \\n \\n \\n \\n \\n 55/20 \\n 57.1 ± 10.1 \\n 75 \\n Can 300mg \\n \\n \\n \\n \\n Inagaki, et al. (2014) [ 29] \\n 60/33 \\n 58.2 ± 11.0 \\n 93 \\n Placebo \\n 24 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 60/33 \\n 58.4 ± 10.4 \\n 93 \\n Can 100mg \\n \\n \\n \\n \\n 72/16 \\n 57.4 ± 11.1 \\n 88 \\n Can 200mg \\n \\n \\n \\n \\n Stenlof, et al. (2013) [ 30] \\n 88/104 \\n 55.7 ± 10.9 \\n 192 \\n Placebo \\n 26 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 81/114 \\n 55.1 ± 10.8 \\n 195 \\n Can 100mg \\n \\n \\n \\n \\n 89/108 \\n 55.3 ± 10.2 \\n 197 \\n Can 300mg \\n \\n \\n \\n \\n Ji, et al. (2019) [ 31] \\n 88/79 \\n 56.9 ± 9.0 \\n 167 \\n Placebo \\n 26 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 95/65 \\n 56.1 ± 9.0 \\n 160 \\n Ert 5mg \\n \\n \\n \\n \\n 98/71 \\n 56.3 ± 9.3 \\n 169 \\n Ert 15mg \\n \\n \\n \\n \\n Terra, et al. (2017) [ 32] \\n 82/71 \\n 56.1 ± 10.9 \\n 153 \\n Placebo \\n 26 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 89/67 \\n 56.8 ± 11.4 \\n 156 \\n Ert 5mg \\n \\n \\n \\n \\n 90/62 \\n 56.2 ± 10.8 \\n 152 \\n Ert 15mg \\n \\n \\n \\n \\n Rosenstock, et al. (2018) [ 44] \\n 98/111 \\n 56.5 ± 8.7 \\n 209 \\n Placebo \\n 26 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 97/110 \\n 56.6 ± 8.1 \\n 207 \\n Ert 5mg \\n \\n \\n \\n \\n 93/112 \\n 56.9 ± 9.4 \\n 205 \\n Ert 15mg \\n \\n \\n \\n \\n Dagogo-Jack S, et al. (2018) [ 33] \\n 100/53 \\n 58.3 ± 9.2 \\n 153 \\n Placebo \\n 52 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 81/75 \\n 59.2 ± 9.3 \\n 156 \\n Ert 5mg \\n \\n \\n \\n \\n 82/71 \\n 59.7 ± 8.6 \\n 153 \\n Ert 15mg \\n \\n \\n \\n \\n Kadowaki, et al. (2014) [ 34] \\n 80/29 \\n 58.7 ± 8.7 \\n 109 \\n Placebo \\n 12 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 84/26 \\n 57.3 ± 11.2 \\n 110 \\n Emp 5mg \\n \\n \\n \\n \\n 77/32 \\n 57.9 ± 9.4 \\n 109 \\n Emp 10mg \\n \\n \\n \\n \\n 84/25 \\n 57.2 ± 9.7 \\n 109 \\n Emp 25mg \\n \\n \\n \\n \\n Søfteland, et al. (2017) [ 35] \\n 60/48 \\n 55.9 ± 9.7 \\n 108 \\n Placebo \\n 24 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 66/43 \\n 54.3 ± 9.6 \\n 109 \\n Emp 10mg \\n \\n \\n \\n \\n 71/39 \\n 55.4 ± 9.9 \\n 110 \\n Emp 25mg \\n \\n \\n \\n \\n Nishimura, et al. (2015) [ 36] \\n 17/4 \\n 60.7 ± 10.8 \\n 21 \\n Placebo \\n 4 \\n AE, SAE \\n \\n \\n 14/6 \\n 64.8 ± 5.9 \\n 20 \\n Emp 10mg \\n \\n \\n \\n \\n 16/3 \\n 62.6 ± 7.8 \\n 19 \\n Emp 25mg \\n \\n \\n \\n \\n Ferrannini, et al. (2013) [ 37] \\n 45/37 \\n 58.0(28–80) \\n 82 \\n Placebo \\n 12 \\n HbA1c,Weight,AE \\n \\n \\n 46/35 \\n 59.0(37–78) \\n 81 \\n Emp 5mg \\n \\n \\n \\n \\n 40/41 \\n 58.0(30–76) \\n 81 \\n Emp 10mg \\n \\n \\n \\n \\n 41/41 \\n 57.0(30–79) \\n 82 \\n Emp 25mg \\n \\n \\n \\n \\n Roden, et al. (2013) [ 38] \\n 123/105 \\n 54.9 ± 10.9 \\n 228 \\n Placebo \\n 24 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 142/82 \\n 56.2 ± 11.6 \\n 224 \\n Emp 10mg \\n \\n \\n \\n \\n 145/79 \\n 53.8 ± 11.6 \\n 224 \\n Emp 25mg \\n \\n \\n \\n \\n Papadopoulou, et al. (2021) [ 39] \\n 21/21 \\n 60.6 ± 9.4 \\n 42 \\n Placebo \\n 12 \\n HbA1c,Weight \\n \\n \\n 23/20 \\n 61.7 ± 6.7 \\n 43 \\n Dap 10mg \\n \\n \\n \\n \\n Yang, et al. (2016) [ 40] \\n 86/59 \\n 53.5 ± 9.2 \\n 145 \\n Placebo \\n 24 \\n HbA1c,Weight,SBP,AE, SAE \\n \\n \\n 67/80 \\n 53.1 ± 9.1 \\n 147 \\n Dap 5mg \\n \\n \\n \\n \\n 88/64 \\n 54.6 ± 9.5 \\n 152 \\n Dap 10mg \\n \\n \\n \\n \\n Bailey, et al. (2010) [ 41] \\n 76/67 \\n 53.7 ± 10.3 \\n 143 \\n Placebo \\n 24 \\n HbA1c,Weight,AE, SAE \\n \\n \\n 69/68 \\n 54.3 ± 9.4 \\n 137 \\n Dap 5mg \\n \\n \\n \\n \\n 77/58 \\n 52.7 ± 9.9 \\n 135 \\n Dap 10mg \\n \\n \\n \\n \\n Weng, et al. (2021) [ 42] \\n 93/68 \\n 55.3 ± 9.5 \\n 161 \\n Placebo \\n 24 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 103/59 \\n 54.3 ± 9.5 \\n 162 \\n Hen 5mg \\n \\n \\n \\n \\n 101/59 \\n 54.7 ± 10.7 \\n 160 \\n Hen 10mg \\n \\n \\n \\n \\n Lu, et al. (2021) [ 43] \\n 100/51 \\n 52.4 ± 10.2 \\n 151 \\n Placebo \\n 24 \\n HbA1c,Weight,SBP,DBP,AE, SAE \\n \\n \\n 88/62 \\n 53.3 ± 9.6 \\n 150 \\n Hen 5mg \\n \\n \\n \\n \\n 115/36 \\n 52.2 ± 9.4 \\n 151 \\n Hen 10mg \\n \\n \\n \\n \\n \\n Fig. 3. \\n \\n The specific evaluation structure Efficacy outcomes \\n HbA1c (main outcome indicator) \\n In the network meta-analysis of HbA1c, 19 interventions across 26 studies were included, involving different doses of seven hypoglycemic drugs: tirzepatide (5 mg, 10 mg, 15 mg), liraglutide (0.6 mg, 1.2 mg, 1.8 mg), canagliflozin (100 mg, 200 mg, 300 mg), ertugliflozin (5 mg, 15 mg), empagliflozin (5 mg, 10 mg, 25 mg), dapagliflozin (5 mg, 10 mg), and henagliflozin (5 mg, 10 mg), as well as placebo. The dot diagram is shown in Fig. 3 A. The heterogeneity test results showed χ 2  = 4.52, I 2  = 0%, P  = 0.95 ( P  &gt; 0.05), indicating no significant heterogeneity among the included studies; thus, a fixed-effects model was used for the combined effect. \\n The league table (Table 3) presents pairwise comparisons between various interventions: all interventions achieved statistically significant improvements compared with placebo. Tirzepatide 15 mg had the most substantial HbA1c reduction (MD [95% CI], −2.24% [−2.52%, −1.96%]), followed by tirzepatide 10 mg (MD [95% CI], −1.99% [−2.29%, −1.69%]), tirzepatide 5 mg (MD [95% CI], −1.82% [−2.11%, −1.53%]), and liraglutide 1.2 mg (MD [95% CI], −1.23% [−1.41%, −1.05%]). The SUCRA rankings for hypoglycemic efficacy are shown in Table 3 and Fig. 4.1 with tirzepatide 15 mg (99.7%) ranked highest, followed by tirzepatide 10 mg (94%), tirzepatide 5 mg (89.6%), liraglutide 1.2 mg (80.6%), and liraglutide 1.8 mg (79.7%).\\n \\n Table 3. \\n League table for HbA1c \\n \\n Fig. 4. \\n \\n SUCRA plots for each outcome indicator Weight (secondary outcome indicator) \\n The network meta-analysis of body weight included 19 interventions from 27 studies with various doses of seven hypoglycemic drugs: tirzepatide (5 mg, 10 mg, 15 mg), liraglutide (0.6 mg, 1.2 mg, 1.8 mg), canagliflozin (100 mg, 200 mg, 300 mg), ertugliflozin (5 mg, 15 mg), empagliflozin (5 mg, 10 mg, 25 mg), dapagliflozin (5 mg, 10 mg), and henagliflozin (5 mg, 10 mg). Placebo was also included in the analysis. The dot diagram is shown in Fig. 3 B. Heterogeneity test results for this analysis were χ2 = 10.09, I 2  = 0%, P  = 0.523 ( P  &gt; 0.05), suggesting homogeneity among studies, supporting the use of a fixed-effects model. \\n The league table (Table 4) shows the effectiveness of each intervention in weight reduction compared to placebo. Tirzepatide 15 mg exhibited the most significant weight reduction (MD [95% CI], −8.74 kg [−9.83 kg, −7.66 kg]), followed by tirzepatide 10 mg (MD [95% CI], −7.13 kg [−8.40 kg, −5.86 kg]). SUCRA rankings for weight loss are indicated in Table 4 and Fig. 4.2, with tirzepatide 15 mg at the top (100%), followed by tirzepatide 10 mg (94.4%), tirzepatide 5 mg (88.9%), canagliflozin 300 mg (78.4%), and empagliflozin 10 mg (65.6%).\\n \\n Table 4. \\n League table for weight \\n \\n SBP (secondary outcome indicator) \\n The network meta-analysis of systolic blood pressure (SBP) included 13 interventions from nine studies. These interventions consisted of various doses of five hypoglycemic drugs. The heterogeneity test results indicated χ 2  = 5.04, I 2  = 0%, P  = 0.538 ( P  &gt; 0.05), suggesting no significant heterogeneity, and a fixed-effects model was applied. \\n The league table (Table 5) displays each intervention’s impact on reducing SBP compared to placebo. Canagliflozin 300 mg showed the most substantial SBP reduction (MD [95% CI], −5.96 mmHg [−7.96 mmHg, −3.96 mmHg]). SUCRA results in Table 5 and Fig. 4.3, rank canagliflozin 300 mg highest (82.1%), followed by dapagliflozin 5 mg (76.1%) and henagliflozin 10 mg (70%).\\n \\n Table 5. \\n League table for SBP \\n \\n DBP (secondary outcome indicator) \\n In the network meta-analysis of diastolic blood pressure (DBP), 11 interventions from eight studies were included, comprising various doses of four hypoglycemic drugs. The heterogeneity test showed χ2 = 5.6, I 2  = 0%, P  = 0.47 ( P  &gt; 0.05), indicating no heterogeneity among studies, supporting a fixed-effects model. \\n The league table (Table 6) shows the DBP reduction effectiveness of each intervention compared to placebo, with henagliflozin 5 mg achieving the best DBP reduction (MD [95% CI], −2.46 mmHg [−3.82 mmHg, −1.10 mmHg]). Table 6 and Fig. 4.4 provides SUCRA results, with henagliflozin 5 mg at the top (78.5%), followed by canagliflozin 300 mg (72.6%) and henagliflozin 10 mg (72.5%).\\n \\n Table 6. \\n League table for DBP \\n \\n AE (secondary outcome indicator) \\n The network meta-analysis of adverse events (AEs) included 19 interventions from 24 studies. The heterogeneity test results for AEs showed χ 2  = 4.4, I 2  = 0%, P  = 0.819 ( P  &gt; 0.05), indicating homogeneity. \\n The league table (Table 7) demonstrated liraglutide 1.8 mg with the highest AE risk (OR [95% CI]: 2.57 [1.78, 3.70]), while empagliflozin 10 mg showed a lower AE risk compared to placebo. SUCRA rankings, provided in Table 7 and Fig. 4.5, indicate liraglutide 1.8 mg at the highest AE risk (98.6%), followed by tirzepatide 15 mg (79.3%), tirzepatide 10 mg (76.6%), tirzepatide 5 mg (74.4%), and henagliflozin 10 mg (70.4%).\\n \\n Table 7. \\n League table for AE \\n \\n SAE (secondary outcome indicator) \\n The network meta-analysis for serious adverse events (SAE) included 19 interventions in 24 studies, with heterogeneity test results χ2 = 2.90, I 2  = 0%, P  = 0.968 ( P  &gt; 0.05), suggesting homogeneity across studies and justifying a fixed-effects model. \\n The league table (Table 8) indicated no significant difference in SAE risk between any interventions and placebo. The top three SUCRA values for SAE likelihood in Table 8 and Fig. 4.6, were ertugliflozin 5 mg (82.9%), tirzepatide 5 mg (68.6%), and empagliflozin 10 mg (66.2%), while the lowest values were tirzepatide 15 mg (31.4%), dapagliflozin 10 mg (28.8%), and empagliflozin 5 mg (25.5%).\\n \\n Table 8. \\n League table for SAE \\n \\n Publication bias \\n Funnel plots were utilized to analyze the differences in average changes across all assessment variables between the treatment and placebo groups. Most of the data points in all of the funnel plots were situated on either side of the vertical axis. They were fundamentally symmetric and may have some level of publication bias. Certain instances exhibit varying levels of asymmetry, indicating the potential presence of publication bias (Fig. 5). \\n Fig. 5. \\n \\n Publication bias Quality assessment of included studies \\n Of the 28 studies, the majority were judged to have low risk of bias in random sequence generation and allocation concealment, with 16 studies meeting these criteria. However, 12 studies presented unclear risk of bias in blinding of outcome assessments due to insufficient details provided on blinding procedures. Notably, one study exhibited a high risk of bias in the blinding of participants and personnel, impacting the reliability of the findings. In terms of incomplete outcome data and selective reporting, most studies were rated as low risk, with only one showing a high risk due to missing data and lack of reported outcomes. Figure 2 illustrates the quality assessment results across all domains, allowing readers to visually interpret the strengths and limitations of each study’s methodological rigor. The overall quality of the included studies supports the robustness of the findings; however, the limitations in blinding procedures should be considered when interpreting the results. Discussion \\n In this meta-analysis, among the 28 trials analyzed, tirzepatide at doses of 5 mg, 10 mg, and 15 mg demonstrated the most significant HbA1c reduction and weight loss, aligning with the findings by Ding et al. [ 5]. As the first dual agonist of GIP and GLP-1 receptors, tirzepatide employs a dual-target mechanism that enables stronger hypoglycemic and weight-reducing effects than other existing hypoglycemic agents, with high tolerability and safety. These qualities underscore its value in comprehensive diabetes management. \\n Obesity and type 2 diabetes share a fundamental pathophysiological mechanism. Research indicates that a weight reduction of 15% or greater can markedly enhance blood sugar regulation in individuals with diabetes, with some attaining a state of \\\"remission\\\" that is not achievable through alternative hypoglycemic treatments [ 45]. The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) regulate blood sugar levels, and tirzepatide targets both GIP and GLP-1 receptors. This dual action helps regulate insulin secretion through GLP-1, delays gastric emptying to reduce appetite, and inhibits gastric acid secretion and motility via GIP, offering an appetite-suppressing effect while potentially preserving islet function. \\n This study indicates that tirzepatide, particularly at doses of 15 mg and 10 mg, shows a higher likelihood of adverse events (AEs) compared to other medications. Tirzepatide 5 mg, however, is associated with a higher probability of serious adverse events (SAEs). Gastrointestinal reactions, such as nausea, vomiting, and diarrhea, are the main AEs of tirzepatide and align with those observed with GLP-1 receptor agonists. In our analysis, liraglutide 1.8 mg has the highest probability of AEs, underscoring a consideration for clinicians when choosing hypoglycemic agents, as hypoglycemia risk is a significant concern. For instance, although insulin effectively lowers blood glucose, its hypoglycemic risk limits its use. In contrast, tirzepatide has a remarkably low hypoglycemia risk when used alone, as indicated by its action mechanism and existing research [ 17 – 20]. This low risk enhances confidence in tirzepatide’s use for blood sugar control, contributing to high compliance with HbA1c targets in the tirzepatide group. \\n Liraglutide, particularly at 1.2 mg and 1.8 mg, shows strong efficacy among GLP-1 receptor agonists, outperforming SGLT2 inhibitors in HbA1c reduction and ranking second to tirzepatide. Evidence shows that liraglutide presents unique benefits relative to other hypoglycemic agents, though its safety profile includes a high probability of AEs, particularly gastrointestinal side effects. Most studies report these adverse effects as mild to moderate, usually diminishing over time with continued treatment. \\n For systolic and diastolic blood pressure reduction, tirzepatide and liraglutide data were limited in the analyzed studies, leading us to focus on SGLT2 inhibitors for these outcomes. Among SGLT2 inhibitors, canagliflozin performed best in lowering both systolic and diastolic blood pressure, followed by henagliflozin. The cardioprotective effects of SGLT2 inhibitors are well-documented and provide considerable benefits for diabetic patients with hypertension [ 9, 10, 46]. The cardiovascular effects of SGLT2 inhibitors may be linked to osmotic diuresis, reduced renal glucose reabsorption, and inhibition of the renin–angiotensin–aldosterone system, contributing to lower blood pressure [ 47, 48]. For example, Zhou et al. [ 49] and Hussein et al. [ 48] showed, through meta-analyses, that SGLT2 inhibitors are associated with reduced risks of cardiovascular death and heart failure hospitalization compared to GLP-1 receptor agonists, while GLP-1 receptor agonists demonstrated stronger HbA1c and weight reduction effects. \\n While tirzepatide may appeal to type 2 diabetic patients seeking weight loss, current evidence on its cardiovascular and renal outcomes is limited. Ongoing studies, expected to conclude in 2025, will provide further insights into these outcomes [ 50]. \\n This network meta-analysis offers a thorough comparison of tirzepatide, liraglutide, and SGLT2 inhibitors, presenting insights into their comparative efficacy and safety profiles, particularly highlighting tirzepatide’s potential for HbA1c reduction and weight loss. Furthermore, using a network meta-analytic framework enables a robust assessment of multiple treatments within a single analysis, facilitating direct and indirect comparisons. Despite these strengths, the study has limitations. First, the number of included studies was small, potentially affecting the generalizability and power of the results. Second, non-English studies were excluded, introducing potential publication bias, and limiting comprehensiveness. Third, the included studies had varying follow-up durations, which might affect the consistency of long-term outcome assessments. Additionally, we could not assess cardiovascular outcomes for GLP-1 receptor agonists or evaluate other GLP-1RAs besides liraglutide, restricting conclusions on their cardiovascular effects. Conclusion \\n Among the seven medications analyzed in this study, tirzepatide exhibits the most significant anti-diabetic and weight loss effects. This is especially beneficial for individuals experiencing obesity or excess weight who are also managing type 2 diabetes. The cardiovascular advantages of tirzepatide are now being investigated. The hypoglycemic effect of Liraglutide1.2mg dosage form above 1.2 mg is better than SGLT2i. SGLT2i has a certain antihypertensive effect and is suitable for patients with diabetes complicated with hypertension or other cardiovascular diseases. The results of this study may provide some reference for clinicians to choose new drugs for diabetes. Nonetheless, considering the limitations identified in this study, it is imperative that additional randomized controlled trials are conducted, featuring larger sample sizes, extended follow-up periods, and rigorous quality standards to substantiate the findings further. Supplementary Information \\n Acknowledgements \\n The authors have no acknowledgments to report. Authors’ contributions\\n \\n Yunjie Teng: Data curation, Formal Analysis, Methodology, Software, Writing – original draft. Xue Fan: Data curation, Software, Writing – original draft. Rui Yu: Formal Analysis, Methodology, Writin–original draft. Xiaoping Yang: Conceptualization, Supervision, Validation, Visualization, Writing – review &amp; editing. All authors contributed to the manuscript and approved the last version for submission. Funding \\n 1. Supported by the founding from Key Laboratory of Special Environment and Health Research in Xinjiang (SKL-SEHR-2024–08). \\n 2. Special Fund Project for Youth Scientific Research in the First Affiliated Hospital of Xinjiang Medical University (2022YFY-QKQN-26). \\n 3. Special Project of Health Care Scientific Research in Xinjiang Uygur Autonomous Region ( BG202405). Data availability\\n \\n All data generated or analysed during this study are included in this published article. Declarations \\n Ethics approval and consent to participate \\n This is a systematic review and meta-analysis, ethics approval and consent to participate are not applicable. Consent for publication \\n Not applicable. This study does not involve human participants. Competing interests \\n The authors declare no competing interests. Footnotes \\n \\n Publisher’s Note \\n Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. \\n References\\n \\n \\n \\n 1. Arnold SV, Khunti K, Tang F, Chen H, Nicolucci A, Gomes MB, Ji L, et al. Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: insights from the DISCOVER prospective cohort study. Endocrinol Diabetes Metab. 2022;5(2):e00321.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 2. Pearson-Stuttard J, Papadimitriou N, Markozannes G, Cividini S, Kakourou A, Gill D, Rizos EC, et al. Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1218–28.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. 10.1016/j.diabres.2021.109119. Epub 2021. Erratum in: Diabetes Res Clin Pract. 2023;204:110945. \\n \\n \\n 4. Sardar MB, Nadeem ZA, Babar M. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024;49(5):102489.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 5. Ding Y, Shi Y, Guan R, Yan S, Liu H, Wang Z, Li J, et al. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Pharmacol Res. 2024;199:107031.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 6. Bechlioulis A, Markozannes G, Chionidi I, Liberopoulos E, Naka KK, Ntzani EE, Liatis S, et al. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: a randomized, prospective, intervention study. J Diabetes Complications. 2023;37(4):108436.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 7. Chen JY, Pan HC, Shiao CC, Chuang MH, See CY, Yeh TH, Yang Y, et al. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovasc Diabetol. 2023;22(1):290.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 9. Sarafidis PA, Tsapas A. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1092.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 10. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 11. Imprialos KP, Stavropoulos K, Doumas M. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(22):2196.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 12. Guan R, Yang Q, Yang X, Du W, Li X, Ma G. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a bayesian network meta-analysis. Front Pharmacol. 2022;13:998816.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 13. Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, Vasilakou D, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206–22.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 14. Ceriello A, Rodbard HW, Battelino T, Brosius F, Cosentino F, Green J, Ji L, et al. Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. Cardiovasc Diabetol. 2023;22(1):277.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 15. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n160.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 16. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142. [ DOI] [ PMC free article] [ PubMed] \\n \\n 17. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2021;398(10295):143–55.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 18. Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938–46.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 19. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet (London, England). 2018;392(10160):2180–93.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 20. Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–29.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 21. Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, Mosenzon O, et al. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2020;22(6):929–37.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 22. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27(8):1915–21.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 23. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161–8.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 24. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–78.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 25. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 26. Yale JF, Xie J, Sherman SE, Garceau C. Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, controlled trial in patients with type 2 diabetes mellitus. Clin Ther. 2017;39(11):2230-42.e2.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 27. Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(6):874–82.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 28. Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15(12):1136–45.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 29. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014;15(11):1501–15.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 30. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–82.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 31. Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, Mu Y, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474–82.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 32. Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–8.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 33. Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–40.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 34. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31(6):621–38.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 35. Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40(2):201–9.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 36. Nishimura R, Tanaka Y, Koiwai K, Inoue K, Hach T, Salsali A, Lund SS, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 37. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–8.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 38. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208–19.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 39. Papadopoulou E, Loutradis C, Tzatzagou G, Kotsa K, Zografou I, Minopoulou I, Theodorakopoulou MP, et al. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. J Hypertens. 2021;39(4):749–58.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 40. Yang W, Han P, Min KW, Wang B, Mansfield T, T’Joen C, Iqbal N, et al. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial. J Diabetes. 2016;8(6):796–808.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 41. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2010;375(9733):2223–33.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 42. Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, et al. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obes Metab. 2021;23(8):1754–64.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 43. Lu J, Fu L, Li Y, Geng J, Qin L, Li P, Zheng H, et al. Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obes Metab. 2021;23(5):1111–20.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 44. Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520–29. [ DOI] [ PubMed] \\n \\n 45. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet (London, England). 2022;399(10322):394–405.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 46. Peikert A, Vaduganathan M, Claggett BL, Kulac IJ, Foà A, Desai AS, Jhund PS, et al. Dapagliflozin in patients with heart failure and previous myocardial infarction: a participant-level pooled analysis of DAPA-HF and DELIVER. Eur J Heart Fail. 2024;26(4):912–24.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 47. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet (London, England). 2021;398(10296):262–76.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 48. Hussein H, Zaccardi F, Khunti K, Davies MJ, Patsko E, Dhalwani NN, Kloecker DE, et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Obes Metab. 2020;22(7):1035–46.\\n [ DOI] [ PubMed] [ Google Scholar] \\n \\n 49. Zhou Z, Zheng M, Zuo Z, Wu T. Comparison of cardiovascular outcomes of new antihyperglycemic agents in type 2 diabetes mellitus: a meta-analysis. ESC Heart Fail. 2024;11(3):1647–56.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n \\n 50. Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2023;381:e074068.\\n [ DOI] [ PMC free article] [ PubMed] [ Google Scholar] \\n Associated Data \\n This section collects any data citations, data availability statements, or supplementary materials included in this article. \\n Supplementary Materials \\n Data Availability Statement \\n All data generated or analysed during this study are included in this published article. \\n \\n \\n\",\n      \"summary\": \"{\\\"answer\\\":\\\"Tirzepatide demonstrates the most effective antidiabetic and weight-reducing effects. Liraglutide at 1.2 mg and above demonstrates a more pronounced hypoglycemic effect in comparison to SGLT2 inhibitors. SGLT2 inhibitors exhibit a distinct hypotensive effect.\\\"}\",\n      \"favicon\": \"https://pmc.ncbi.nlm.nih.gov/static/img/favicons/favicon-32x32.png\"\n    },\n    {\n      \"id\": \"https://pubmed.ncbi.nlm.nih.gov/38388874/\",\n      \"title\": \"Tirzepatide: A Review in Type 2 Diabetes - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/38388874/\",\n      \"publishedDate\": \"2023-12-19T00:00:00.000Z\",\n      \"author\": \"Nicole L France 1 , Yahiya Y Syed 2\",\n      \"text\": \"## Abstract\\n\\nTirzepatide (Mounjaro®), a first-in-class dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is approved for use as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM) in the USA, EU, Japan and other countries. It comes as single-dose prefilled pens and single-dose vials. In phase III SURPASS trials, once-weekly subcutaneous tirzepatide, as monotherapy or add-on-therapy to oral glucose-lowering medications and insulin, was superior to the GLP-1 receptor agonists (RAs) dulaglutide 0.75 mg and semaglutide 1 mg as well as basal and prandial insulin for glycaemic control and weight loss in adults with inadequately controlled T2DM. Tirzepatide was generally well tolerated, with a safety profile consistent with that of GLP-1 RAs. Tirzepatide was associated with a low risk of clinically significant or severe hypoglycaemia and no increased risk of major adverse cardiovascular events. Adverse events were mostly mild to moderate in severity, with the most common being gastrointestinal events including nausea, diarrhoea, decreased appetite and vomiting. In conclusion, tirzepatide is a valuable addition to the treatment options for T2DM.\\n\\n## Plain language summary\\n\\nMany people with type 2 diabetes mellitus (T2DM) do not achieve and maintain glycaemic and weight management goals using currently available treatments. Tirzepatide (Mounjaro®) is the first incretin-based glucose-lowering medication to be approved as an add-on to diet and exercise in adults with T2DM that targets both the glucose-dependent insulinotropic polypeptide receptor (GIP) and the glucagon-like peptide-1 (GLP-1) receptor. In patients with inadequately controlled T2DM, tirzepatide improved glycaemic control and body weight more so than dulaglutide 0.75 mg, semaglutide 1 mg and insulin when used on its own or in combination with other medications. Tirzepatide was generally well tolerated and had a low risk of hypoglycaemia. The most common adverse events were usually short-lived gastrointestinal-related events, which were generally mild to moderate in nature, including nausea, diarrhoea, decreased appetite and vomiting. Tirzepatide is a valuable addition to the treatment options for people with inadequately controlled T2DM.\\n\\n© 2024\\\\. The Author(s), under exclusive licence to Springer Nature Switzerland AG.\\n\\n[PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\\n\\n## Similar articles\\n\\n- [Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.](https://pubmed.ncbi.nlm.nih.gov/38407177/)\\n\\n\\n\\nUrva S, Levine JA, Schneck K, Tang CC.Urva S, et al.Curr Med Res Opin. 2024 Apr;40(4):567-574. doi: 10.1080/03007995.2024.2322072. Epub 2024 Mar 12.Curr Med Res Opin. 2024.PMID: 38407177\\n\\n- [Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.](https://pubmed.ncbi.nlm.nih.gov/36050763/)\\n\\n\\n\\nNauck MA, D'Alessio DA.Nauck MA, et al.Cardiovasc Diabetol. 2022 Sep 1;21(1):169. doi: 10.1186/s12933-022-01604-7.Cardiovasc Diabetol. 2022.PMID: 36050763Free PMC article.Review.\\n\\n- [The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.](https://pubmed.ncbi.nlm.nih.gov/34819089/)\\n\\n\\n\\nFisman EZ, Tenenbaum A.Fisman EZ, et al.Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.Cardiovasc Diabetol. 2021.PMID: 34819089Free PMC article.\\n\\n- [Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/38400569/)\\n\\n\\n\\nStefanou MI, Theodorou A, Malhotra K, Aguiar de Sousa D, Katan M, Palaiodimou L, Katsanos AH, Koutroulou I, Lambadiari V, Lemmens R, Giannopoulos S, Alexandrov AV, Siasos G, Tsivgoulis G.Stefanou MI, et al.Eur Stroke J. 2024 Sep;9(3):530-539. doi: 10.1177/23969873241234238. Epub 2024 Feb 23.Eur Stroke J. 2024.PMID: 38400569Free PMC article.\\n\\n\\n## Cited by\\n\\n- [Polypharmacology: new drugs in 2023-2024.](https://pubmed.ncbi.nlm.nih.gov/40095348/)\\n\\n\\n\\nRyszkiewicz P, Malinowska B, Schlicker E.Ryszkiewicz P, et al.Pharmacol Rep. 2025 Jun;77(3):543-560. doi: 10.1007/s43440-025-00715-8. Epub 2025 Mar 17.Pharmacol Rep. 2025.PMID: 40095348Free PMC article.Review.\\n\\n- [Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models.](https://pubmed.ncbi.nlm.nih.gov/40430489/)\\n\\n\\n\\nTartau CG, Boboc IKS, Mititelu-Tartau L, Bogdan M, Buca BR, Pavel LL, Amalinei C.Tartau CG, et al.Pharmaceuticals (Basel). 2025 May 1;18(5):670. doi: 10.3390/ph18050670.Pharmaceuticals (Basel). 2025.PMID: 40430489Free PMC article.Review.\\n\\n- [Peptide-based therapeutic and delivery strategies for inflammatory bowel disease: challenges and future directions.](https://pubmed.ncbi.nlm.nih.gov/40686644/)\\n\\n\\n\\nGe C, Wang Z, Wang Y, Wei M.Ge C, et al.RSC Adv. 2025 Jul 18;15(31):25560-25578. doi: 10.1039/d5ra03731j. eCollection 2025 Jul 15.RSC Adv. 2025.PMID: 40686644Free PMC article.Review.\\n\\n- [Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF.](https://pubmed.ncbi.nlm.nih.gov/40186193/)\\n\\n\\n\\nLuo L, Zuo Y, Dai L.Luo L, et al.Cardiovasc Diabetol. 2025 Apr 4;24(1):155. doi: 10.1186/s12933-025-02707-7.Cardiovasc Diabetol. 2025.PMID: 40186193Free PMC article.Review.\\n\\n- [Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.](https://pubmed.ncbi.nlm.nih.gov/39335551/)\\n\\n\\n\\nCaturano A, Galiero R, Rocco M, Tagliaferri G, Piacevole A, Nilo D, Di Lorenzo G, Sardu C, Vetrano E, Monda M, Marfella R, Rinaldi L, Sasso FC.Caturano A, et al.Biomedicines. 2024 Sep 7;12(9):2039. doi: 10.3390/biomedicines12092039.Biomedicines. 2024.PMID: 39335551Free PMC article.Review.\\n\\n\\n## References\\n\\n1. Goyal RJI. Type 2 diabetes. \\\\[updated 2023 June 23\\\\] In: StatPearls \\\\[Internet\\\\]. Treasure Island (FL): StatPearls Publishing; Jan. 2023. [https://www.ncbi.nlm.nih.gov/pubmed/30020625](https://www.ncbi.nlm.nih.gov/pubmed/30020625) . Accessed 19 Dec 2023.\\n1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.\\n -\\n[DOI](https://doi.org/10.2337/dci22-0034)-\\n[PubMed](https://pubmed.ncbi.nlm.nih.gov/36148880/)-\\n[PMC](https://pmc.ncbi.nlm.nih.gov/articles/10008140/)\\n1. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–S157.\\n -\\n[DOI](https://doi.org/10.2337/dc23-s009)-\\n[PubMed](https://pubmed.ncbi.nlm.nih.gov/36507650/)\\n1. Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021;12(1):143–57.\\n -\\n[DOI](https://doi.org/10.1007/s13300-020-00981-0)-\\n[PubMed](https://pubmed.ncbi.nlm.nih.gov/33325008/)\\n1. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.\\n -\\n[DOI](https://doi.org/10.1111/dom.13129)-\\n[PubMed](https://pubmed.ncbi.nlm.nih.gov/29364588/)\\n\\n## Publication types\\n\\n## MeSH terms\\n\\n## Substances\\n\\n## LinkOut - more resources\\n\\n- ### Full Text Sources\\n\\n\\n - [Springer](https://dx.doi.org/10.1007/s40265-023-01992-4)\\n- ### Medical\\n\\n\\n - [MedlinePlus Health Information](https://medlineplus.gov/diabetestype2.html)\",\n      \"summary\": \"{\\\"answer\\\":\\\"Tirzepatide (Mounjaro®), a dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is approved for use as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM). In phase III SURPASS trials, once-weekly subcutaneous tirzepatide was superior to the GLP-1 receptor agonists dulaglutide and semaglutide as well as basal and prandial insulin for glycaemic control and weight loss in adults with inadequately controlled T2DM. Tirzepatide was generally well tolerated and had a low risk of hypoglycaemia. The most common adverse events were gastrointestinal-related events, which were generally mild to moderate in nature, including nausea, diarrhoea, decreased appetite and vomiting.\\\"}\",\n      \"image\": \"https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image-v2.jpg\"\n    }\n  ],\n  \"searchTime\": 5154.3,\n  \"costDollars\": {\n    \"total\": 0.009,\n    \"search\": {\n      \"neural\": 0.005\n    },\n    \"contents\": {\n      \"text\": 0.002,\n      \"summary\": 0.002\n    }\n  }\n}\n## Executive Summary\n\nRecent high-quality evidence from 2019–2024 demonstrates that tirzepatide, a dual GIP/GLP-1 receptor agonist, is the most effective pharmaceutical agent for glycemic control and weight reduction in adults with type 2 diabetes, surpassing both GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and SGLT2 inhibitors. Tirzepatide is generally well tolerated, with gastrointestinal side effects being the most common, and carries a low risk of hypoglycemia. SGLT2 inhibitors remain notable for their antihypertensive and cardioprotective effects, making them suitable for diabetic patients with comorbid hypertension.\n\n---\n\n## Introduction\n\nDiabetes mellitus, particularly type 2 diabetes (T2DM), poses a growing global health burden, necessitating effective and safe pharmacologic interventions. The period from 2019 to 2024 has seen the approval and clinical evaluation of several novel agents, most notably tirzepatide, alongside established GLP-1 receptor agonists and SGLT2 inhibitors. This synthesis analyzes the comparative efficacy and safety of these agents, focusing on glycemic outcomes, weight effects, blood pressure, and adverse events, based on recent systematic reviews, meta-analyses, and pivotal clinical trials.\n\n---\n\n## Main Findings by Theme\n\n### 1. Glycemic Control (HbA1c Reduction)\n\n- **Tirzepatide** (5, 10, 15 mg weekly) demonstrated the greatest HbA1c reductions among all agents studied. Tirzepatide 15 mg reduced HbA1c by a mean difference (MD) of −2.24% vs. placebo (95% CI: −2.52, −1.96), outperforming GLP-1 RAs (e.g., liraglutide 1.2 mg, MD −1.23%) and SGLT2 inhibitors (e.g., canagliflozin 300 mg, MD −1.00%).[^1]\n- **GLP-1 receptor agonists** (e.g., liraglutide) remain effective, with higher doses (>1.2 mg) achieving superior glycemic control compared to SGLT2 inhibitors.[^1]\n- **SGLT2 inhibitors** provide significant but lesser HbA1c reductions relative to tirzepatide and high-dose GLP-1 RAs.[^1]\n\n### 2. Weight Reduction\n\n- **Tirzepatide** again led in weight loss: 15 mg weekly resulted in a mean reduction of −8.74 kg compared to placebo (95% CI: −9.83, −7.66), with lower doses also outperforming all comparators.[^1,^2]\n- **GLP-1 RAs** and **SGLT2 inhibitors** also reduced weight, but to a lesser degree (e.g., canagliflozin 300 mg: −2.31 kg).[ ^1]\n- The magnitude of weight loss with tirzepatide is clinically meaningful and associated with improved diabetes control and potential remission in some cases.[^1,^2]\n\n### 3. Blood Pressure Effects\n\n- **SGLT2 inhibitors** demonstrated the most pronounced antihypertensive effects, with canagliflozin 300 mg reducing systolic blood pressure by −5.96 mmHg (95% CI: −7.96, −3.96) and henagliflozin 5 mg most effective for diastolic pressure (−2.46 mmHg).[ ^1]\n- **Tirzepatide** and **GLP-1 RAs** had limited data on blood pressure effects in the analyzed studies, but SGLT2 inhibitors are recommended for T2DM patients with comorbid hypertension due to their blood pressure–lowering and cardioprotective properties.[^1,^2]\n\n### 4. Safety and Adverse Events\n\n- **Tirzepatide** and **GLP-1 RAs** are generally well tolerated; gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common but typically mild to moderate and transient.[^1,^2]\n- **Tirzepatide**: Higher doses (10–15 mg) are associated with increased risk of adverse events (AEs), but serious adverse events (SAEs) are not significantly different from placebo or comparators.[^1]\n- **GLP-1 RAs**: Liraglutide 1.8 mg was associated with the highest AE risk among agents studied.[^1]\n- **SGLT2 inhibitors**: Generally had a favorable safety profile, with some agents (e.g., empagliflozin 10 mg) showing lower AE rates than placebo.[^1]\n- **Hypoglycemia risk** is low with tirzepatide and GLP-1 RAs when used alone, and SGLT2 inhibitors do not increase hypoglycemia risk unless combined with insulin or sulfonylureas.[^1,^2]\n\n### 5. Cardiovascular and Renal Outcomes\n\n- **SGLT2 inhibitors** have robust evidence for reducing cardiovascular and renal events in T2DM.[^1]\n- **Tirzepatide**: Early data suggest no increased risk of major adverse cardiovascular events; ongoing studies are evaluating its long-term cardiovascular and renal benefits.[^2]\n- **GLP-1 RAs** (e.g., liraglutide) have demonstrated cardiovascular and renal protection in earlier studies, but only liraglutide was included in the referenced meta-analysis.[^1]\n\n---\n\n## Critical Analysis of Evidence Quality\n\n- **Strengths**: \n    - The primary network meta-analysis included 28 randomized controlled trials (RCTs) with 8,499 participants, using robust methodology (PRISMA, PROSPERO registration, Cochrane risk of bias assessment).[^1]\n    - Consistent findings across multiple large phase III trials (e.g., SURPASS) and systematic reviews support the superiority of tirzepatide for glycemic and weight outcomes.[^1,^2]\n- **Limitations**:\n    - Limited direct evidence for type 1 diabetes (all studies focused on T2DM).\n    - Some included studies had unclear or high risk of bias in blinding and outcome assessment.[^1]\n    - Follow-up durations varied (4–52 weeks), potentially limiting long-term safety and efficacy conclusions.\n    - Only liraglutide was assessed among GLP-1 RAs; evidence for other agents (e.g., semaglutide) is extrapolated from separate trials.\n    - Non-English studies were excluded, introducing possible publication bias.\n    - Cardiovascular outcome data for tirzepatide are still emerging.\n\n---\n\n## Synthesis of Key Insights and Patterns\n\n- **Tirzepatide** is the most effective agent for both glycemic control and weight loss in T2DM, offering a new standard for patients inadequately controlled on existing therapies.\n- **GLP-1 RAs** remain highly effective, especially at higher doses, and offer proven cardiovascular benefits.\n- **SGLT2 inhibitors** are optimal for patients with T2DM and comorbid hypertension or cardiovascular/renal disease due to their unique blood pressure–lowering and organ-protective effects.\n- **Safety profiles** are generally favorable across all classes, with gastrointestinal symptoms most prominent for incretin-based therapies and low hypoglycemia risk when used as monotherapy.\n\n---\n\n## Limitations and Gaps\n\n- Lack of data for type 1 diabetes: All findings pertain to type 2 diabetes.\n- Limited long-term and real-world safety data for tirzepatide.\n- Cardiovascular and renal outcomes for tirzepatide remain under investigation.\n- Comparative data for newer GLP-1 RAs (e.g., semaglutide) and other dual agonists are limited in head-to-head settings.\n- Exclusion of non-English studies may limit global generalizability.\n\n---\n\n## Evidence-Based Conclusions\n\n- **Tirzepatide** (approved 2022) is currently the most effective pharmaceutical for glycemic control and weight loss in adults with type 2 diabetes, with a favorable safety profile and low hypoglycemia risk.[^1,^2]\n- **GLP-1 RAs** (e.g., liraglutide) remain excellent options, particularly for patients prioritizing glycemic control and weight loss, and have established cardiovascular benefits.\n- **SGLT2 inhibitors** are preferred for patients with hypertension or cardiovascular/renal comorbidities.\n- All three classes are superior to placebo and older agents for key diabetes outcomes, with choice tailored to patient comorbidities, preferences, and tolerability.\n\n---\n\n## Future Research Directions\n\n- Long-term cardiovascular and renal outcome trials for tirzepatide (results expected by 2025).\n- Head-to-head comparisons between tirzepatide and other GLP-1 RAs (e.g., semaglutide) in diverse populations.\n- Real-world effectiveness and safety studies, especially in underrepresented groups.\n- Exploration of combination therapies involving these novel agents.\n- Further research on effects in type 1 diabetes and special populations (e.g., elderly, those with advanced renal disease).\n\n---\n\n## References\n\n[^1]: [Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC11668020/) (2024).\n[^2]: [Tirzepatide: A Review in Type 2 Diabetes](https://pubmed.ncbi.nlm.nih.gov/38388874/) (2023).\n\n---\n\n**No major errors or issues were identified in the tool output; however, it is important to note the absence of direct data for type 1 diabetes and the ongoing nature of long-term cardiovascular safety studies for tirzepatide.**\n# Analysis of Recent Advances in Diabetes Management (2019-2024)\n\n## Summary of Key Pharmaceutical and Non-Pharmaceutical Approaches\n\nBased on the search results provided, I've synthesized the most significant recent developments in diabetes management, covering both pharmaceutical and non-pharmaceutical approaches with strong clinical evidence.\n\n### Non-Pharmaceutical Approaches\n\n**1. Automated Insulin Delivery (AID) Systems**\n- **Technology**: Combines continuous glucose monitoring (CGM) with insulin pumps/pods to automatically adjust insulin delivery\n- **Clinical Evidence**: Studies show \"unequivocal improvement in glycemic outcomes across all age groups\" (Endocrine Reviews 2023)\n- **Benefits**: Reduces hypoglycemia/hyperglycemia risk, decreases management burden, improves HbA1c, and increases time-in-range\n- **Types**:\n  - Hybrid closed-loop systems (e.g., Tandem t:slim x2, Medtronic MiniMed 780G, Omnipod 5)\n  - Fully closed-loop systems (e.g., iLet Bionic Pancreas)\n- **Limitations**: Data fatigue and integration challenges for both patients and providers\n\n**2. Digital Health Tools & Connected Care**\n- Remote monitoring platforms show HbA1c reductions up to 1.5% and fewer hypoglycemic episodes\n- AI-driven predictive analytics can forecast adverse glycemic events\n- Automation can reduce clinician documentation time by approximately 30%\n- Only about 40% of digital diabetes solutions see active clinical use, largely due to poor workflow integration\n\n**3. Implementation Challenges**\n- Both clinicians and patients report data overload and burnout\n- Successful adoption requires human-centered design and seamless integration into daily workflows\n- User experience and simplicity are critical for effectiveness\n\n### Pharmaceutical Treatments\n\n**1. Tirzepatide (Mounjaro®)**\n- **Class**: Dual GIP/GLP-1 receptor agonist (approved 2022)\n- **Efficacy**: Most effective agent for both glycemic control and weight loss\n  - HbA1c reduction: -2.24% vs. placebo (15mg dose)\n  - Weight reduction: -8.74kg vs. placebo (15mg dose)\n- **Administration**: Once-weekly subcutaneous injection\n- **Safety**: Generally well-tolerated; primarily gastrointestinal side effects (nausea, diarrhea, decreased appetite)\n- **Advantages**: Low hypoglycemia risk, superior to both GLP-1 RAs and SGLT2 inhibitors\n\n**2. GLP-1 Receptor Agonists (e.g., Liraglutide)**\n- Strong efficacy for glycemic control, especially at higher doses (>1.2mg)\n- Significant weight loss benefits\n- Established cardiovascular benefits\n- Similar side effect profile to tirzepatide (primarily gastrointestinal)\n\n**3. SGLT2 Inhibitors**\n- Notable for blood pressure reduction and cardiovascular/renal protection\n- Canagliflozin 300mg showed greatest systolic BP reduction (-5.96 mmHg)\n- Recommended for diabetic patients with hypertension or cardiovascular disease\n- Moderate glycemic and weight effects compared to incretin-based therapies\n\n## Evidence Quality and Limitations\n\n- Strong evidence from multiple RCTs, systematic reviews, and meta-analyses\n- Most data focused on type 2 diabetes; limited information on type 1 diabetes\n- Variable follow-up durations (4-52 weeks) in pharmaceutical studies\n- Cardiovascular outcome data for tirzepatide still emerging (expected 2025)\n- Limited head-to-head comparisons between newest agents\n\n## Clinical Implications\n\n1. **Personalized Approach**: Treatment selection should consider:\n   - Comorbidities (especially cardiovascular/renal disease and hypertension)\n   - Weight management goals\n   - Technology comfort and data management capabilities\n   - Preference for injection vs. oral administration\n\n2. **Integration Challenges**: Both pharmaceutical and technological interventions require attention to:\n   - Workflow integration for clinicians\n   - User experience and simplicity for patients\n   - Data management strategies to prevent burnout\n\n3. **Future Directions**: Ongoing research into:\n   - Long-term cardiovascular outcomes for tirzepatide\n   - Further refinement of closed-loop insulin delivery systems\n   - More seamless integration of digital health tools into clinical practice\n\nThis synthesis reflects the most current evidence-based approaches to diabetes management, highlighting the complementary roles of pharmaceutical innovation and technological advancement in improving outcomes for people with diabetes."
]